Elan Pharmaceuticals, Inc.

The Texas A&M University System

Sarah Wright

Irene Griswold-Prenner

Theodore A Yednock

Russell E Rydel

Gregory J Bix

Nikolay Malinin

Maile Skomp

Irene Griswald Prenner

The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of A&#x3b2; peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.

Use of perlecan domain V in treating amyloidogenic disease

The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.

Methods of inhibiting amyloid toxicity

Methods and compositions for suppressing amyloid-mediated inhibition of long-term potentiation (LTP) are provided.

Methods of treating cognitive impairment

The invention provides a novel human protein, FISH adaptor protein, involved in amyloid &#x3b2;-protein-mediated cell death. Also provided are methods for modulating amyloid &#x3b2;-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein.

Growing community of inventors

San Francisco, CA, United States of America

Sarah Wright